Quantcast
Last updated on April 18, 2014 at 9:13 EDT

Latest Adjuvant Stories

2014-03-11 08:29:04

Presentation on March 25, 2014 at 2:10 PM EDT PRINCETON, N.J., March 11, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that its Chief Scientific Officer, Robert N. Brey, PhD, will give a presentation on the "Development of Thermostable Subunit Vaccines" at the...

2013-12-17 08:30:18

SAN DIEGO, Dec. 17, 2013 /PRNewswire/ -- Pfenex Inc. today announced that Leidos Holdings, Inc. (NYSE: LDOS) (formerly SAIC) has awarded Pfenex a subcontract in support of the development of an anthrax vaccine containing its recombinant protective antigen (rPA) and a novel, immune-enhancing adjuvant. The prime contract was awarded to Leidos by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to improve the efficacy of...

2013-12-12 12:14:07

Pretreatment with near-infrared laser also could improve response to additional intradermal vaccines Pretreating the site of intradermal vaccination – vaccine delivered into the skin rather than to muscles beneath the skin – with a particular wavelength of laser light may substantially improve vaccine effectiveness without the adverse effects of chemical additives currently used to boost vaccine efficacy. In the open-access journal PLOS ONE, investigators from Vaccine and Immunotherapy...

2013-11-12 12:25:13

DUBLIN, November 12, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/t8bqtz/adjuvants_market) has announced the addition of the "Adjuvants Market in Agriculture by Type and Application - Global Trends & Forecasts to 2018" [http://www.researchandmarkets.com/research/t8bqtz/adjuvants_market ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The global agriculture adjuvant market...

2013-11-04 08:26:49

Solutions company to improve the efficacy of public health and bioterror countermeasures by developing, manufacturing, applying and testing a novel adjuvant for West Nile virus and anthrax vaccine candidates. RESTON, Va., Nov. 4, 2013 /PRNewswire/ -- Leidos (NYSE: LDOS), a national security, health and engineering solutions company, announced it has been awarded a prime vaccine adjuvant development contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of...

2013-10-29 12:28:04

Additional funding allocated to research nanoemulsion-adjuvanted HIV vaccine ANN ARBOR, Mich., Oct. 29, 2013 /PRNewswire/ -- NanoBio Corporation today announced that the company has been awarded an initial contract worth $5.5 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop a nanoemulsion (NE) adjuvant for use with a pandemic influenza vaccine. The total contract is valued at approximately...

2013-09-11 08:29:01

Pre-clinical data demonstrates the ability of nanoemulsion-adjuvanted vaccines to provide immunogenicity and protection against illness and disease ANN ARBOR, Mich., Sept. 11, 2013 /PRNewswire/ -- NanoBio Corporation today announced that the company will present new data at the 53(rd) Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting showing the safety and efficacy of a nanoemulsion (NE) adjuvanted intramuscular vaccine for the prevention of respiratory...

2013-05-29 08:30:36

NEWARK, Del., May 29, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) today announced that a patent to increase influenza vaccine performance through the use of iBio's proprietary iBioModulator fusion protein technology has been allowed in China. The patent, which will issue from Chinese patent application No.: 200780008098.3, will further broaden the territories in which patent exclusivity has been secured for this novel technology. In the U.S., the technology is covered by issued U.S....

2013-05-22 08:27:27

PRINCETON, N.J., May 22, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that the US Patent and Trademark Office granted patent 8,444,991 entitled "Method of Preparing an Immunologically-Active Adjuvant-Bound Dried Vaccine Composition." The new patent's claims encompass...

2013-04-09 16:24:05

LONDON, April 9, 2013 /PRNewswire/ -- Bioradar UK Ltd and Replikins Ltd announced today that a new completely synthetic H7N9 Replikins Vaccine is ready for testing. The news comes on the heels of four new cases of avian flu (H7N9) reported in China, bringing the total to 28 cases, 8 of whom have died from the virus. The new vaccine is produced without any biological substances and will be used without adjuvants, similar to the H5N1 Synthetic Replikins Vaccine which was found effective (1)....